SWOG Study S1501 Patient Information

Heart problems from cancer therapy are a growing concern.

Help doctors learn ways to reduce and manage heart problems for metastatic breast cancer patients.

Consider participating in a breast cancer study

We are recruiting women and men with metastatic breast cancer to SWOG S1501, a clinical trial that will help us learn if adding a blood pressure medication (carvedilol) to HER-2 targeted therapy will prevent cardiotoxicity, or damage to the heart.

Cancer treatment can cause side effects, including heart problems

Carvedilol (Coreg) is a medication (pill or capsule) used to treat congestive heart failure and high blood pressure. It is not a new medication. In small studies, it has been shown to protect the heart from side effects of chemotherapy. This study compares the effects of taking carvedilol to the standard approach for treating your cancer. The standard approach is to wait until a heart condition might develop.

To participate in the study:

You must be

  • Diagnosed with HER-2 positive metastatic breast cancer

  • At increased risk of cardiotoxicity due to previous chemotherapy (anthracycline) exposure OR at least one risk factor for heart disease

  • Starting or continuing trastuzumab-based (Herceptin) HER-2 targeted therapy

AND

You must not

  • Be dialysis dependent
  • Have uncontrolled asthma

Read more about the study here: https://www.clinicaltrials.gov/ct2/show/NCT03418961.

More Information

v2 06/01/2021